Theriva Biologics (TOVX) Live Share Price, Invest From India

Theriva Biologics Stock Performance

as on June 19, 2026 at 2:16 pm IST

Day's High
$0.25
Day's Price Range
$0.27
$0.25
8.00%
Upside
52 Week's Low
52 Week's High
$0.16
52-Week Price Range
$0.86
$0.25
34.88%
Downside
245.28%
Upside

Theriva Biologics share price movements today

Previous Close: $0.27
Open: $0.27
Volume: 1.7M
Day's Low - High: $0.25 - $0.27
52 Week Low - High: $0.16 - $0.86

Theriva Biologics Historical Returns

1 Month Return: -20.03 %
3 Month Return: + 29.63 %
1 Year Return: -41.92 %
3 Year Return: -98.48 %
5 Year Return: 0 %

Theriva Biologics Stock Fundamentals & Key Indicators

Check Theriva Biologics market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$11.5M

EPS (TTM)

-0.2

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

PEG Ratio

EBITDA

-12.6M

Revenue (TTM)

300.0K

Profit Margin

0.00%

Return On Equity TTM

-138.91%

Theriva Biologics vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Theriva Biologics with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %	Dividend Yield %
Theriva Biologics	BUY	$11.5M	NA	NA	0.00%	NA
Alnylam Pharmaceuticals Common Stock	BUY	$37.1B	60.79%	69.87	12.55%	NA
Vertex PharmaceuticalsCommon Stock	BUY	$114.6B	139.12%	26.8	35.51%	NA
Regeneron Pharmaceuticals Common Stock	BUY	$63.9B	14.22%	14.88	29.65%	0.59%

Stock Returns calculator for Theriva Biologics Stock including INR - Dollar returns

The Theriva Biologics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

Theriva Biologics investment value today

Current value as on today

₹63,330

Returns

-₹36,670

(-36.67%)

Returns from Theriva Biologics Stock

-₹41,860 (-41.86%)

Dollar Impact

₹5,191 (+5.19%)

Analyst Recommendation on Theriva Biologics Stock

Based on 8 analysts

BUY

87.50%

Buy

12.50%

Hold

0.00%

Sell

Based on 8 analysts, 87.5% of analysts recommend a 'BUY' rating for Theriva Biologics. Average target price of $2.5

Theriva Biologics Share Price Target

Get share price movements and forecasts by analysts on Theriva Biologics.

What analysts predicted

90%UPSIDE

Target Price

$2.5

Current Price

$0.25

Analyzed by

8 Analysts

Target

$2.50

Theriva Biologics target price $2.5, a slight upside of 90% compared to current price of $0.25. According to 8 analysts rating.

Indian Investors' Interest in Theriva Biologics Stock

Search interest for Theriva Biologics Stock has decreased by -14% in the last 30 days, reflecting a downward trend in search activity.

Time period: May 23, 2026 to June 22, 2026

Change:-14% versus previous 30 day period

Theriva Biologics Quarterly Profit & Loss

All numbers in Millions USD

	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Total Revenue	0	-	-	-	0	-	-	-	-	0
Gross Profit	0	0	0	0	0	0	0	-	0	0
Operating Income	-5	-5	-8	-7	-4	-4	-13	-4	-2	-2
EBITDA	-5	-5	-4	-5	-4	-4	-13	-4	-1	-2
Interest Expense	0	-	-	-	0	-	-	-	-	-
Depreciation	0	0	0	0	0	0	0	0	0	0
Income Before Tax	-5	-5	-8	-7	-4	-4	-13	-4	-1	-2
Income Tax Expense	0	0	-	-	0	-	-	-	1	-
Net Income	-5	-5	-8	-7	-4	-4	-13	-4	-1	-2
Net Profit Margin	-723.61%	0.00%	0.00%	0.00%	-2887.66%	0.00%	0.00%	0.00%	0.00%	-681.33%

Theriva Biologics Annual Profit & Loss

All numbers in Millions USD

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Revenue	-	-	-	-	-	-	-	-
Gross Profit	0	0	0	0	0	0	0	0
Operating Income	-17	-15	-10	-14	-21	-21	-26	-15
EBITDA	-17	-15	-9	-14	-19	-21	-19	-23
Interest Expense	-	-	-	0	0	-	-	-
Depreciation	0	0	0	0	0	0	0	0
Income Before Tax	-13	-15	-10	-14	-21	-19	-25	-23
Income Tax Expense	-4	0	0	0	-1	-1	-	1
Net Income	-13	-15	-10	-14	-19	-18	-25	-25
Net Profit Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Theriva Biologics Quarterly Cash Flow

All numbers in Millions USD

	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Net Income	-5	-8	-7	-4	-4	-13	-4	-1	-2
Operating Cash Flow	-4	-3	-3	-4	-4	-4	-4	-2	-2
Investing Cash Flow	-	0	-	-	-	0	0	-	-
Financing Cash Flow	-	1	3	0	3	6	0	8	3
Change in Cash	-4	-1	0	-4	-1	2	-4	5	1

Theriva Biologics Annual Cash Flow

All numbers in Millions USD

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Net Income	-15	-13	-15	-10	-14	-19	-18	-25	-23
Operating Cash Flow	-20	-17	-13	-12	-12	-19	-18	-16	-16
Investing Cash Flow	0	0	0	0	0	-4	0	0	0
Financing Cash Flow	18	29	3	3	74	-1	0	5	18
Change in Cash	-1	11	-13	-8	61	-25	-18	-11	1

Insights on Theriva Biologics

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

NO EFFECT
Against Peers
In the last 1 year, Regeneron Pharmaceuticals, Inc. Common Stock has given 19.7% return, outperforming this stock by 61.6%
NO EFFECT
Against Peers
In the last 3 years, Theriva Biologics, Inc. has experienced a drawdown of -98.5%, however Alnylam Pharmaceuticals, Inc. Common Stock resisted the overall trend and outperformed by 76.7%
NEGATIVE IMPACT
Price Dip
In the last 7 days, TOVX stock has moved down by -14.6%

About Theriva Biologics

Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. Its lead product candidate, VCN-01 (zabilugene almadenorepvec), a clinical stage oncolytic human adenovirus that is in Phase 1 clinical trials and Phase 2 VIRAGE trial for patients with pancreatic cancer, head and neck squamous cell carcinoma, ovarian cancer, colorectal cancer, and retinoblastoma. The company also develops VCN-11 for treating solid tumors; SYN-004 (ribaxamase), an oral capsule prophylactic therapy that is in Phase 1b/2a clinical trials for the prevention of acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT); and SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) for multiple gastrointestinal and metabolic indications. In addition, it develops clinical stage products, such as SYN-006 to prevent aGVH, clostridioides difficile infection, and microbiome damage in patients treated with carbapenem antibiotics; and SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics. The company has a license agreement with Rasayana Therapeutics, Inc. to research, develop, manufacture, and commercialize any product that includes SYN-020, as well as a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Theriva Biologics, Inc. is headquartered in Rockville, Maryland.

Organisation	Theriva Biologics
Headquarters	9605 Medical Center Drive, Rockville, MD, United States, 20850
Industry	Biotechnology
CEO	Mr. Steven A. Shallcross CPA
E-voting on shares	Click here to vote

Key Management of Theriva Biologics

Name	Title
Mr. Steven A. Shallcross CPA	CEO, CFO, Treasurer, Corporate Secretary & Director
Dr. Vince Wacher Ph.D.	Senior Vice President of Corporate & Product Development
Dr. Ramon Alemany Ph.D.	Senior Vice President of Discovery

FAQs

What is Theriva Biologics share price today?

Theriva Biologics share price today is $0.25 as on June 19, 2026 at 8:46 am IST at the close of the market. Theriva Biologics share today touched a day high of $0.27 and a low of $0.25.

What is the 52 week high and 52 week low for Theriva Biologics share?

Theriva Biologics share touched a 52 week high of $0.86 on October 15, 2025 and a 52 week low of $0.16 on February 23, 2026. Theriva Biologics stock price today i.e. June 19, 2026 at 8:46 am IST is closed at $0.25,which is 71.04% down from its 52 week high and 53.56% up from its 52 week low.

What is Theriva Biologics's market capitalisation today?

Theriva Biologics market capitalisation is $0.00T as on June 19, 2026 at 8:46 am IST.

How to invest in Theriva Biologics Stock (TOVX) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Theriva Biologics on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Theriva Biologics Shares that will get you 6.0000 shares as per Theriva Biologics share price of $0.25 per share as on June 19, 2026 at 8:46 am IST.

What is the minimum amount required to buy Theriva Biologics Stock (TOVX) from India?

Indian investors can start investing in Theriva Biologics (TOVX) shares with as little as ₹94.31 or $1 (as of June 22, 2026 at 9:44 am IST) using the INDmoney app.
For example: If you want to invest $10 or ₹943.10 in Theriva Biologics stock (as per the Rupee-Dollar exchange rate as on June 22, 2026 at 9:44 am IST). Based on Theriva Biologics share’s latest price of $0.25 as on June 19, 2026 at 8:46 am IST, you will get 40.0000 shares of Theriva Biologics. Learn more about fractional shares .